NAKA Battle Card: Risk, Performance & Setup | Stoxcraft

Nakamoto Inc.

Health

Performance

9.8

Risk

Sell

Buy

Curious about the Scores? Learn more.

Nakamoto Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

27.06.2026

Rock bottom. The fall’s complete, stability nowhere to be found.

27.06.2026

Momentum tanked. Clearly underperforming.

27.05.2026

Red alert. Risk levels out of control.

01.01.2026

Danger zone. Balance sheet’s flashing red across the board.

NAKA

Nakamoto Inc.

4.92

-0.71%

9.8

Sell

Buy

© Stoxcraft

Nakamoto Inc.

Nakamoto Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Nakamoto Inc. do? Business model and key facts

Get the full picture of Nakamoto Inc.: what it builds, where it operates, and how it makes money.

Nakamoto Inc. Profile

Sector: Financial Services

Industry: Financial - Capital Markets

Employees (FY): 65

Nakamoto Inc. develops and invests in a global portfolio of Bitcoin-native companies. The company provides commercial and financial infrastructure for the capital markets. The company was formerly known as Kindly MD, Inc. and change its name to Nakamoto Inc. in January 2026. The company was incorporated in 2019 and is based in Nashville, Tennessee.

Company facts

David Forrest Bailey

CEO

65

Employees worldwide

Performance

-98.37%

Last 12 months

Growth

$1.82M

Revenue year

$-52,228,923

Net income

Valuation

$82.66M

Market Cap

-1.35

Price/Earnings Ratio

Stocks related to Nakamoto Inc.

Selected based on industry alignment and relative market positioning.

XAU.TO

Goldmoney Inc.

14.13

-3.29%

4.6

Sell

Buy

© Stoxcraft

Goldmoney Inc.

FUFU

BitFuFu Inc.

1.30

+0.78%

8.5

Sell

Buy

© Stoxcraft

BitFuFu Inc.

ABTC

American Bitcoin Corp

6.44

+4.04%

9.8

Sell

Buy

© Stoxcraft

American Bitcoin Corp

Events and news impacting Nakamoto Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Low-poly Toroshi watches a cracked $68.8 million BaaS partner loan block trigger the collapse of CCB’s profit tower despite a Q2 revenue beat.

CCB beat revenue. One bad loan partner still cost it 47%.

CCB beat revenue. One bad loan partner still cost it 47%.

Coastal Financial beat Q2 revenue estimates and is down 44% in a month. A single BaaS partner's $68.8 million credit charge explains the crash.

HypeMeter-img

Toroshi scanning UNH healthcare mech before earnings — Stoxcraft score analysis

UnitedHealth (UNH) nears its 52-week high ahead of its earnings date. The score isn't buying it.

5 min 18 sec read

UnitedHealth (UNH) nears its 52-week high ahead of its earnings date. The score isn't buying it.

UnitedHealth (UNH) sits 2% below its 52-week high. The stock is up 41% in a year. Its own scorecard is not nearly as impressed.

HypeMeter-img

Slightly Bullish

Toroshi presents five stock fighters labeled ACMR, MXL, HUM, BJRI, and SN in a futuristic low-poly arena.

June's 5 strongest-trending stocks: the fundamentals aren't equal

5 min 24 sec read

June's 5 strongest-trending stocks: the fundamentals aren't equal

Humana just hit a 52-week high. Analysts keep raising price targets. Its performance score still says something's off.

HypeMeter-img

Slightly Bullish

Best Financial Stocks 2026: Exchange Operators Lead While Banks Fall

Best financial stocks in 2026: Stoxcraft score ranking

4 min 45 sec read

Best financial stocks in 2026: Stoxcraft score ranking

The financials sector is splitting hard right now. Exchange operators are surging. Banks are bleeding score points. Here's what the data says about where quality sits.

HypeMeter-img

Berkshire Cash Pile and the Buffett Quality Screen in 2026

Berkshire's $397B cash pile: which stocks pass a quality screen right now

10 min 19 sec read

Berkshire's $397B cash pile: which stocks pass a quality screen right now

Berkshire Hathaway holds $397B in cash and still isn't buying. The market keeps asking why. The better question is which stocks actually pass the quality bar right now.

HypeMeter-img

Cboe Global Markets stock analysis 2026 casino market metaphor

Cboe Global Markets scores contradict the bearish retail narrative: a Stoxcraft analysis

5 min 24 sec read

Cboe Global Markets scores contradict the bearish retail narrative: a Stoxcraft analysis

Cboe Global Markets runs the VIX and the S&P 500 options exchange. It's printing record earnings in calm and turbulent markets alike. Almost no retail investor has it on their watchlist.

HypeMeter-img

Slightly Bullish

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Company Spotlight

4 min 12 sec read

Why is Eli Lilly down 23% while Mounjaro keeps growing?

Lilly grew revenue 43% last quarter. Its stock is down 23% since January. Today's Q1 2026 earnings decide which story the market believes.

HypeMeter-img

A futuristic low-poly bull in a high-tech lab outfit scans a glowing DNA strand, highlighting how deeper analysis can reveal hidden signals and overlooked value in biotech data like United Therapeutics.

United Therapeutics stock: what the data says about UTHR

8 min 45 sec read

United Therapeutics stock: what the data says about UTHR

United Therapeutics carries a Health Score of 99 out of 100 and a net margin above 41%. Up 66% in 12 months. Here's what the fundamentals show.

HypeMeter-img

Slightly Bullish

A focused bull analyzes a glowing DNA structure inside a futuristic lab, symbolizing the complexity behind biotech innovation. While most investors see uncertainty, the real value often lies in understanding what others overlook.

United Therapeutics (UTHR) is the most undervalued large-cap biotech right now

Tech & Innovation

6 min 20 sec read

United Therapeutics (UTHR) is the most undervalued large-cap biotech right now

United Therapeutics just posted a fourth straight year of record revenue. It's debt-free, generating $4.7B in cash, and trades at half the P/E of its peers. The market still hasn't figured this one out.

HypeMeter-img

Low-poly, gaming-inspired hospital scene featuring the Stoxcraft bull as a doctor holding a large GLP-1 injector while consulting a patient, symbolizing Hims &amp; Hers expanding into weight-loss treatments.

HIMS stock up 57%: what the Novo deal really means

8 min 46 sec read

HIMS stock up 57%: what the Novo deal really means

Hims & Hers just had its best week on record. Novo Nordisk dropped the lawsuit. Now HIMS sells Ozempic and Wegovy at $149–$299/month. This changes everything.

HypeMeter-img

Stylized low-poly bull real estate investor standing in a commercial property district, looking at a glowing “667 Streak” sign symbolizing Realty Income’s record of consecutive monthly dividend payments.

The dividend stock that hasn't missed a payment in 30 years

6 min 42 sec read

The dividend stock that hasn't missed a payment in 30 years

Realty Income has paid investors every month for 30 years straight. That streak survived 2008 and COVID without a single miss. The stock's Stoxcraft scores tell a more complicated story.

HypeMeter-img

Low poly bull observing falling domino blocks labeled margin, options, debt and leverage during market selloff

11 February 2026

Are markets overleveraged? Why this selloff feels different

11 February 2026

3 min 31 sec read

Are markets overleveraged? Why this selloff feels different

Red days stacking up. But is this just fear… or leveraged positioning getting flushed out?

HypeMeter-img

Toroshi leads five market force heroes representing rates, cash flow, AI infrastructure, geopolitics, and liquidity.

07 January 2026

The 5 biggest forces shaping the stock market outlook

07 January 2026

8 min 45 sec read

The 5 biggest forces shaping the stock market outlook

Markets don't move on headlines. They move on forces most people miss until it's too late. Here are the five that are shaping where stocks go next.

HypeMeter-img

Slightly Bullish

Best Performing Stocks Right Now Across All 11 Market Sectors

13 October 2025

Who's really winning the market right now

13 October 2025

18 min 36 sec read

Who's really winning the market right now

Thirty-three stocks. Eleven sectors. One cheat sheet. Most people only watch tech. That's a mistake. Here's who's really winning the market right now.

HypeMeter-img

Slightly Bullish

Nakamoto Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.